base
control
clinic
trial
demonstr
mark
decreas
need
intub
well
improv
morbid
mortal
noninvas
ventil
niv
consid
firstlin
ventilatori
treatment
select
patient
sever
exacerb
chronic
obstruct
pulmonari
diseas
copd
hypercapn
respiratori
failur
patient
show
benefit
use
niv
affect
acut
cardiogen
pulmonari
oedema
cpo
niv
continu
posit
airway
pressur
cpap
equal
effect
decreas
need
intub
improv
mortal
patient
final
immunosuppress
patient
poor
outcom
develop
pulmonari
infiltr
acut
hypoxem
respiratori
failur
ahrf
patient
niv
seem
decreas
need
intub
relat
morbid
mortal
benefit
niv
appear
consequ
avoid
tracheal
intub
associ
morbid
mortal
morbid
includ
increas
risk
ventilatorassoci
pneumonia
vap
ventilatorinduc
lung
injuri
increas
need
sedat
contribut
prolong
ventil
complic
upper
airway
relat
prolong
translaryng
intub
howev
role
niv
type
patient
still
debat
possibl
popul
risk
complic
relat
invas
mechan
ventil
may
benefit
use
niv
howev
efficaci
niv
patient
differ
type
ahrf
less
evid
control
clinic
trial
although
patient
ahrf
less
like
requir
tracheal
intub
niv
ad
standard
therapi
systemat
review
literatur
support
routin
use
niv
patient
ahrf
due
less
clear
effect
mortal
heterogen
found
among
studi
suggest
effect
vari
among
differ
popul
first
problem
address
patient
ahrf
heterogen
condit
studi
assess
outcom
patient
ahrf
treat
niv
intens
care
unit
icu
identifi
european
journal
intern
medicin
differ
group
patient
substanti
differ
outcom
among
fig
moreov
major
clinic
trial
assess
efficaci
niv
patient
ahrf
studi
mix
popul
patient
controversi
result
trial
analys
togeth
contrast
studi
assess
specif
use
niv
patient
pneumonia
even
consid
controversi
due
major
variabl
failur
rate
gener
higher
observ
copd
acut
cpo
studi
niv
often
includ
pneumonia
heterogen
condit
ahrf
independ
associ
niv
failur
multicentr
studi
howev
larg
publish
seri
hospitalis
patient
communityacquir
pneumonia
cap
report
high
rate
chronic
respiratori
cardiac
comorbid
henc
recent
report
patient
cap
treat
niv
icu
report
substanti
proport
patient
previou
cardiac
respiratori
diseas
result
high
proport
hypercapn
respiratori
failur
among
henc
outcom
niv
patient
cap
studi
exclud
copd
hypercapn
patient
extrapol
gener
cap
popul
treat
niv
communityacquir
pneumonia
signific
caus
morbid
mortal
sever
cap
conceptu
pneumonia
requir
admiss
icu
carri
high
risk
death
direct
admiss
icu
requir
patient
septic
shock
acut
respiratori
failur
arf
requir
invas
mechan
ventil
defin
major
sever
criteria
current
infecti
diseas
societi
america
idsa
american
thorac
societi
at
guidelin
use
defin
sever
cap
admiss
icu
also
recommend
patient
minor
sever
criteria
tabl
idsaat
guidelin
recommend
patient
three
minor
sever
criteria
absenc
major
criteria
admit
icu
among
criteria
defin
sever
cap
need
invas
ventil
sever
arteri
hypoxem
increas
respiratori
rate
relat
arf
cornerston
treatment
pneumonia
antibiot
therapi
ventilatori
support
patient
sever
respiratori
failur
import
rational
use
niv
overcom
episod
sever
acut
respiratori
failur
arf
without
need
invas
mechan
ventil
background
use
niv
sever
cap
relat
presenc
sever
arf
invas
ventil
indic
case
lifethreaten
respiratori
failur
howev
invas
ventil
associ
increas
risk
sever
complic
sinc
main
object
niv
sever
arf
gener
help
overcom
acut
episod
without
need
invas
mechan
ventil
avoid
tracheal
intub
morbid
mortal
would
decreas
patient
pneumonia
patient
treat
niv
persist
associ
poor
outcom
literatur
first
studi
found
associ
retrospect
analysi
episod
arf
patient
copd
exacerb
niv
effect
fail
patient
need
tracheal
intub
invas
mechan
ventil
among
other
univari
analysi
assess
predictor
niv
failur
found
pneumonia
caus
exacerb
associ
higher
failur
niv
studi
pneumonia
caus
unsuccess
episod
success
episod
arf
failur
rate
patient
caus
exacerb
failur
rate
patient
pneumonia
multin
studi
icu
analys
evolut
patient
receiv
niv
episod
sever
ahrf
relat
aetiolog
episod
among
differ
caus
ahrf
highest
rate
tracheal
intub
correspond
patient
acut
respiratori
distress
syndrom
ard
cap
fig
multivari
analysi
predictor
niv
failur
found
presenc
ard
cap
signific
independ
predictor
niv
failur
adjust
oddsratio
independ
predictor
niv
failur
age
older
year
higher
score
sever
icu
admiss
wors
hypoxemia
h
niv
treatment
anoth
prospect
studi
analys
patient
without
underli
chronic
respiratori
diseas
treat
niv
sever
cap
arf
gener
use
niv
follow
decreas
respiratori
rate
increas
arteri
hypoxemia
min
return
baselin
valu
niv
remov
howev
overal
intub
rate
patient
among
other
advanc
age
lower
level
arteri
oxygen
predictor
intub
likewis
intub
associ
higher
mortal
longer
length
hospit
stay
contrast
patient
niv
avoid
intub
favour
outcom
due
good
outcom
patient
tracheal
intub
avoid
fact
assess
efficaci
niv
result
minim
delay
intub
author
studi
suggest
patient
may
undergo
trial
niv
appropri
monitor
order
avoid
unnecessari
delay
intub
conflict
favour
physiolog
respons
niv
poor
clinic
evolut
patient
sever
cap
observ
anoth
studi
patient
sever
ahrf
sever
cap
cpo
group
similar
baselin
level
arteri
hypoxemia
respiratori
rate
heart
rate
improv
arteri
hypoxemia
heart
rate
similar
group
patient
respiratori
frequenc
improv
patient
cpo
niv
appli
likewis
intub
rate
higher
hospit
length
stay
longer
patient
pneumonia
expect
hospit
mortal
rate
substanti
higher
intub
nonintub
patient
light
result
conclud
patient
sever
ahrf
need
niv
whose
caus
respiratori
failur
pneumonia
among
wors
outcom
even
similar
level
arteri
hypoxemia
howev
prospect
randomis
clinic
trial
need
order
assess
whether
niv
effect
patient
sever
cap
control
trial
assess
efficaci
niv
patient
sever
pneumonia
prospect
randomis
control
trial
patient
sever
cap
includ
patient
alloc
receiv
convent
treatment
without
niv
studi
demonstr
patient
receiv
niv
togeth
convent
treatment
lower
rate
tracheal
intub
vs
p
b
shorter
stay
intermedi
care
unit
receiv
convent
treatment
although
length
hospit
stay
hospit
mortal
similar
group
studi
also
show
subset
analysi
signific
benefit
niv
occur
patient
copd
hypercapn
respiratori
failur
subset
patient
also
lower
mortal
two
month
vs
p
contrast
patient
without
copd
hypercapn
respiratori
failur
benefit
niv
although
result
promis
routin
use
niv
patient
cap
without
copd
clearli
establish
recent
prospect
randomis
control
trial
patient
sever
ahrf
demonstr
niv
decreas
need
tracheal
intub
icu
mortal
compar
highconcentr
oxygen
therapi
moreov
subgroup
analysi
observ
patient
pneumonia
caus
episod
ahrf
niv
show
signific
benefit
subset
patient
benefit
decreas
tracheal
intub
icu
mortal
remain
regard
subset
patient
nonsignific
trend
lower
rate
niv
failur
patient
thorac
trauma
niv
failur
patient
studi
cpo
ard
low
high
respect
without
differ
patient
treat
niv
control
group
studi
use
niv
result
faster
improv
arteri
hypoxemia
tachypnea
compar
highconcentr
oxygen
therapi
fig
likewis
niv
also
associ
lower
rate
septic
shock
trend
lower
incid
hospitalacquir
pneumonia
concern
rais
due
high
mortal
rate
patient
fail
niv
treatment
particularli
ahrf
without
previou
cardiac
respiratori
diseas
de
novo
arf
possibl
unnecessari
delay
intub
result
excess
mortal
particularli
actual
mortal
patient
intub
niv
failur
higher
mortal
predict
sever
score
report
howev
comparison
may
mislead
sinc
sever
score
often
underestim
hospit
mortal
icu
patient
recent
preliminari
report
use
niv
patient
cap
sever
arf
found
first
time
consist
associ
delay
intub
increas
mortal
patient
cap
de
novo
arf
longer
durat
niv
intub
relat
sever
patient
admiss
studi
moreov
patient
shock
need
intub
fail
niv
earlier
without
shock
therefor
excess
mortal
attribut
author
delay
intub
rather
severelyil
select
popul
contrast
relationship
found
delay
intub
mortal
patient
cap
previou
cardiac
respiratori
diseas
studi
summari
patient
sever
cap
receiv
niv
support
sever
ahrf
among
highest
rate
niv
failur
reason
niv
indic
patient
manag
set
appropri
resourc
staff
equip
correct
monitor
order
earli
detect
evid
niv
failur
therefor
avoid
unnecessari
delay
intub
patient
howev
appropri
select
patient
sever
cap
addit
niv
standard
treatment
may
decreas
likelihood
need
intub
earli
applic
niv
may
extrem
help
immunosuppress
patient
pulmonari
infiltr
necessarili
associ
ali
intub
dramat
increas
risk
pneumonia
infect
icu
mortal
two
trial
evalu
niv
oppos
standard
treatment
alon
immunosuppress
patient
characteris
respiratori
rate
breathsmin
pao
fio
mmhg
antonelli
et
al
compar
niv
vs
standard
therapi
solid
organ
transplant
recipi
ahrf
within
first
hour
treatment
pao
fio
improv
patient
niv
group
patient
receiv
medic
therapi
alon
niv
associ
signific
reduct
rate
intub
complic
mortal
durat
icu
stay
among
survivor
patient
immunosuppress
secondari
haematolog
malign
transplant
human
immunodefici
viru
infect
hilbert
et
al
compar
earli
niv
standard
treatment
patient
fever
bilater
pulmonari
infiltr
hypoxemia
fewer
patient
niv
group
requir
intub
seriou
complic
die
icu
hospit
shown
niv
especi
appli
earli
significantli
amelior
condit
patient
reduc
need
intub
overal
mortal
first
report
use
niv
outsid
icu
patient
respiratori
failur
hematopoiet
progenitor
transplant
publish
recent
principi
et
al
describ
use
niv
directli
haematolog
unit
univers
hospit
prospect
clinic
studi
histor
match
control
compar
efficaci
earli
administr
noninvas
cpap
deliv
helmet
vs
face
mask
treat
haematolog
malign
patient
fever
pulmonari
infiltr
hypoxem
acut
respiratori
failur
pao
fio
mmhg
total
patient
enrol
mean
pao
fio
around
oxygen
improv
patient
noninvas
cpap
patient
fail
helmet
cpap
intoler
eight
patient
mask
group
cpap
could
appli
continu
longer
period
time
helmet
group
author
conclud
earli
cpap
helmet
improv
oxygen
select
immunosuppress
patient
hypoxem
acut
respiratori
failur
even
outsid
icu
inde
toler
helmet
cpap
seem
better
cpap
deliv
mask
sever
new
inform
principi
studi
first
assess
safeti
feasibl
niv
outsid
icu
haematolog
patient
sever
arf
second
appli
particular
interfac
helmet
probabl
simplest
easiest
way
appli
cpap
outsid
protect
unit
sinc
requir
electr
power
andor
need
ventil
helmet
howev
use
caution
especi
hypercapn
patient
appli
pressur
support
ventil
commonli
use
ventil
due
possibl
co
rebreath
poor
patientventil
interact
third
studi
indirectli
highlight
interdisciplinari
collabor
haematologist
intensivist
appear
crucial
achiev
earli
implement
niv
improv
qualiti
care
one
year
later
rabitsh
et
al
analys
retrospect
efficaci
niv
patient
ahrf
autolog
allogen
stem
cell
transplant
directli
ventil
bone
marrow
transplant
unit
niv
deliv
standard
face
mask
helmet
eightytwo
patient
develop
respiratori
failur
patient
initi
intub
mechan
ventil
none
patient
surviv
thirtyf
patient
initi
underw
niv
seven
patient
surviv
discharg
hospit
eleven
patient
improv
within
first
h
niv
respect
oxygen
regard
respond
survivor
partial
pressur
arteri
oxygen
pao
improv
initi
niv
nonsurvivor
pao
improv
patient
p
author
conclud
patient
arf
stem
cell
transplant
niv
could
improv
prognosi
compar
group
patient
constantli
die
receiv
mechan
ventil
use
niv
sever
acut
respiratori
syndrom
sar
airborn
diseas
gener
debat
base
toronto
experi
sar
certain
number
caregiv
contract
sar
patient
intub
follow
failur
niv
use
niv
discourag
patient
two
subsequ
observ
studi
china
howev
found
evid
viral
spread
caregiv
took
appropri
precaut
event
bird
flu
pandem
ventil
resourc
like
sever
strain
niv
may
offer
mean
support
afflict
mainli
initi
respiratori
failur
howev
niv
often
consid
contraind
respiratori
failur
communic
respiratori
airborn
diseas
unless
use
within
neg
pressur
isol
room
strict
precaut
taken
sever
experiment
studi
shown
substanti
exposur
exhal
air
within
radiu
patient
receiv
niv
differ
facial
mask
especi
higher
level
posit
pressur
continu
posit
airway
pressur
use
treat
arf
sever
condit
alveoli
collaps
due
increas
transpulmonari
pressur
airway
close
pressur
collaps
alveoli
particip
ga
exchang
repres
common
exampl
intrathorac
shunt
mechan
hypoxemia
typic
respond
oxygen
administr
case
way
improv
ga
exchang
alveolar
recruit
induc
cpap
patient
breath
constant
resist
supraatmospher
pressur
increas
airway
pressur
present
whole
breath
cycl
particular
posit
endexpiratori
pressur
peep
allow
collaps
alveoli
remain
open
also
expir
mean
alveoli
particip
ga
exchang
thu
lead
improv
oxygen
due
shunt
effect
decreas
improv
ventilationperfus
ratio
lead
increas
function
residu
capac
frc
complianc
increas
decreas
work
breath
effect
cpap
respiratori
system
demonstr
mani
year
ago
et
al
anoth
model
patient
acut
parenchym
respiratori
failur
subject
admit
icu
acut
cpo
applic
higher
level
peep
yield
decreas
transpulmonari
pressur
parallel
decreas
pulmonari
pressur
similarli
higher
peep
valu
associ
greater
level
oxygen
decreas
intrapulmonari
shunt
recent
lher
et
al
evalu
effect
peep
patient
acut
lung
injuri
pneumonia
studi
compar
shortterm
effect
cpap
cmh
combin
niv
pressuresupport
ventil
psv
inspiratori
support
level
cmh
posit
endexpiratori
pressur
peep
cmh
psv
inspiratori
support
level
cmh
peep
cmh
psv
compar
spontan
breath
respiratori
frequenc
decreas
highest
level
inspiratori
support
psv
contrast
arteri
oxygen
improv
similarli
psv
increas
fail
reach
statist
signific
psv
final
work
breath
decreas
modal
niv
cpap
fig
although
highest
reduct
dyspnoea
achiev
psv
howev
author
discuss
major
limit
specif
cpap
experiment
set
state
disappoint
result
observ
cpap
may
explain
part
type
patient
interfac
ventil
use
deliv
cpap
moreov
author
point
low
level
psv
appli
initi
final
period
compens
dead
space
impos
circuit
measur
apparatu
howev
psv
level
ad
cpap
trial
although
design
compens
load
impos
circuit
spontan
breath
one
exclud
absenc
low
psv
level
cpap
trial
could
explain
part
tidal
volum
decreas
note
switch
initi
baselin
cpap
accord
observ
variat
airway
pressur
patient
could
consid
cpap
fairli
administ
ventil
author
conclud
whether
differ
system
type
administr
highflow
cpap
vs
ventil
helmet
vs
facemask
would
give
differ
result
may
warrant
investig
effect
helmet
cpap
pneumonia
evalu
cosentini
et
al
recent
studi
patient
pneumonia
effect
oxygen
helmet
cpap
compar
venturi
mask
patient
moderatetosever
hypoxemia
pao
fio
ratio
primari
endpoint
time
reach
pao
fio
ratio
fortyseven
patient
recruit
randomis
cpap
control
receiv
oxygen
patient
randomis
cpap
reach
endpoint
median
h
wherea
control
reach
end
point
h
p
proport
patient
reach
primari
endpoint
among
cpap
group
among
control
p
howev
h
reach
primari
endpoint
patient
cpap
group
maintain
pao
fio
valu
suggest
peep
rapidli
effect
appli
longer
period
obtain
clinic
relev
effect
howev
effect
oxygen
appli
longer
period
time
therefor
possibl
decreas
efficaci
cpap
time
observ
studi
delclaux
test
author
conclud
cpap
deliv
helmet
rapidli
improv
oxygen
patient
cap
suffer
moder
hypoxem
arf
therefor
studi
may
repres
proofofconcept
evalu
potenti
use
cpap
patient
cap
sinc
similar
effect
oxygen
observ
delcalux
studi
obtain
mix
popul
includ
patient
acut
cardiogen
pulmonari
edema
circulatori
effect
cpap
applic
effect
studi
appli
mainli
patient
arf
cardiac
origin
congest
heart
failur
acut
cpo
inde
increas
intrathorac
pressur
induc
applic
peep
decreas
venou
return
usual
elev
patient
heart
failur
especi
reduc
eject
fraction
moreov
increas
intrathorac
pressur
reduc
transmur
left
ventricular
systol
pressur
consequ
decreas
ventricular
afterload
may
produc
increas
cardiac
output
patient
acut
cpo
diastol
dysfunct
increas
intrathorac
pressur
induc
peep
applic
benefit
cpap
result
decreas
left
ventricular
enddiastol
volum
ie
preload
cardiovascular
effect
cpap
patient
pneumonia
less
known
venou
return
decreas
induc
peep
applic
ia
l
c
p
p
p
v
p
v
f
l
may
impair
stroke
volum
patient
frequent
febril
rel
absolut
hypovolem
may
lead
net
unfavour
effect
balanc
blood
oxygen
tissu
oxygen
deliveri
cardiovascular
effect
studi
cosentini
et
al
systol
diastol
blood
pressur
togeth
heart
rate
significantli
modifi
h
cpap
applic
similarli
haemodinam
data
unchang
h
venturi
mask
oxygen
administr
compar
cardiovascular
find
observ
cpap
group
tabl
data
systol
blood
pressur
heart
rate
analys
delclaux
et
al
unfortun
hypoxem
patient
randomis
cpap
vs
oxygen
alon
belong
heterogen
group
diseas
rang
acut
heart
failur
neardrown
sirsshock
make
imposs
draw
conclus
haemodinam
effect
subset
patient
pneumonia
case
overal
heart
rate
significantli
decreas
group
h
icu
without
differ
cpap
oxygen
therapi
convers
systol
blood
pressur
unchang
h
icu
group
conclus
scarc
data
haemodinam
effect
cpap
applic
patient
pneumonia
insuffici
make
evidencebas
suggest
howev
demonstr
effect
venou
return
decreas
peep
applic
alert
physician
monitor
haemodynam
effect
cpap
consid
option
treat
patient
arf
secondari
pneumonia
patient
volum
alway
assess
cpap
applic
fluid
reason
administ
counterbal
expect
effect
peep
intrathorac
circul
volum
first
attempt
appli
posit
pressur
ventil
immunosuppress
patient
although
haematolog
disord
made
late
earli
use
cpap
mainli
patient
acquir
immunodefici
syndrom
acut
respiratori
failur
due
pneumocysti
jiroveci
infect
formerli
known
p
carinii
pneumonia
pcp
kesten
et
al
appli
nasal
cpap
subject
pcp
patient
show
oxygen
improv
min
nasal
cpap
without
supplement
oxygen
mean
pao
increas
mmhg
calcul
alveolararteri
oxygen
gradient
decreas
mm
hg
two
year
later
gregg
et
al
treat
aid
patient
pcp
mask
cpap
mean
pao
rose
mmhg
respiratori
rate
decreas
breathsmin
paco
unchang
mean
durat
treatment
day
one
patient
develop
pneumothorax
major
complic
mortal
rate
later
author
report
use
cpap
arf
due
pcp
patient
mortal
rate
rang
studi
although
uncontrol
conclud
cpap
deliv
via
nasal
face
mask
effect
support
therapi
acut
ill
patient
although
author
highlight
attent
paid
possibl
occurr
pneumothorax
acut
lung
injuri
common
cours
haematolog
malign
hilbert
et
al
publish
prospect
studi
cpap
efficaci
treatment
febril
neutropen
patient
arf
patient
fever
normocapn
arf
defin
pao
fio
ratio
mmhg
treat
cpap
facial
mask
cpap
administ
mean
period
h
first
h
mean
durat
cpap
day
reduct
respiratori
rate
less
breathsmin
achiev
patient
mean
pao
fio
ratio
increas
mmhg
cpap
success
avoid
endotrach
intub
patient
total
respond
four
nonrespond
surviv
multivari
analysi
simplifi
acut
physiolog
score
sap
ii
hepat
failur
entri
studi
predict
cpap
failur
author
conclud
cpap
effici
case
surviv
control
studi
need
confirm
efficaci
noninvas
cpap
evalu
appropri
select
immunosuppress
patient
recent
efficaci
earli
cpap
vs
oxygen
alon
evalu
prospect
randomis
control
studi
squadron
et
al
author
enrol
consecut
neutropen
patient
radiolog
evid
bilater
pulmonari
infiltr
spo
breath
room
air
respiratori
rate
breath
min
randomis
control
oxygen
venturi
mask
fio
helmet
cpap
fio
plu
peep
cmh
patient
receiv
cpap
less
need
icu
admiss
mechan
ventil
vs
patient
p
cpap
reduc
rel
risk
develop
need
ventilatori
support
confid
interv
among
patient
admit
icu
intub
rate
lower
cpap
control
group
vs
patient
p
cpap
reduc
rel
risk
intub
confid
interv
author
suggest
earli
use
cpap
haematolog
ward
patient
earli
chang
respiratori
variabl
prevent
evolut
acut
lung
injuri
requir
mechan
ventil
icu
admiss
conclus
cpap
applic
treatment
arf
immunosuppress
patient
seem
effect
term
ga
exchang
physiolog
variabl
also
reduct
endotrach
intub
mortal
effect
mortal
reduct
probabl
driven
decreas
eti
rate
sinc
endotrach
intub
subpopul
associ
disproportion
high
mortal
rate
due
immunodefici
risk
tubeassoci
fatal
infect
first
report
applic
cpap
treatment
arf
immunocompet
popul
date
back
three
patient
sever
hypoxemia
pao
fio
ratio
righttoleft
pulmonari
shunt
greater
secondari
influenza
treat
increment
peep
valu
pao
mmhg
righttoleft
shunt
fallen
less
two
three
patient
requir
mechan
ventil
surviv
one
die
neurolog
complic
cardiopulmonari
arrest
despit
clear
chest
xray
film
improv
ga
exchang
author
conclud
treatment
cpap
safe
use
adult
practic
well
theoret
benefit
cpap
author
report
year
later
patient
chickenpox
pneumonia
success
treat
cpap
first
randomis
control
studi
compar
cpap
oxygen
alon
publish
delclaux
et
al
enrol
consecut
patient
admit
icu
sever
arf
pao
fio
ratio
mmhg
popul
consist
patient
pneumonia
acut
pulmonari
oedema
remain
case
baselin
h
heart
rate
beatsmin
baselin
h
despit
initi
physiolog
improv
patient
treat
cpap
h
treatment
median
pao
fio
ratio
greater
cpap
patent
oxygen
alon
fig
final
outcom
significantli
differ
two
treatment
applic
cpap
fail
reduc
endotrach
intub
rate
vs
standard
therapi
group
p
hospit
mortal
vs
p
icu
length
stay
higher
number
advers
event
occur
cpap
treatment
vs
p
author
conclud
despit
earli
physiolog
improv
cpap
neither
reduc
need
intub
improv
outcom
patient
acut
hypoxem
nonhypercapn
respiratori
insuffici
primarili
due
acut
lung
injuri
howev
sever
concern
rais
studi
first
titl
studi
state
hypoxem
nonhypercapn
patient
enrol
howev
exclus
criteria
acut
respiratori
acidosi
defin
ph
paco
mmhg
copd
mean
patient
aliard
may
enrol
initi
acut
respiratori
acidosi
ph
paco
mmhg
inde
patient
treat
cpap
median
respiratori
rate
breathsmin
percentil
median
ph
paco
mmhg
second
hypothesi
indirectli
confirm
author
state
larg
proport
patient
enrol
met
definit
ard
demonstr
neg
prognost
factor
hypoxem
arf
togeth
pneumonia
third
among
patient
enrol
pneumonia
henc
hard
conclud
studi
cpap
effect
pneumonia
sinc
result
describ
accord
subgroup
diseas
acut
cpo
neardrown
sirsshock
fourth
among
patient
randomis
oxygen
alon
switch
cpap
author
indic
whether
outcom
attribut
initi
treatment
arm
final
pneumonia
infecti
diseas
surviv
associ
correct
antibiot
therapi
support
measur
discuss
paper
conclus
sinc
trial
conduct
strictli
hypoxem
patient
pneumonia
rather
heterogen
hypoxemichypoxemichypercapn
subject
mainli
suffer
ard
data
add
limit
evidencebas
inform
efficaci
cpap
pneumonia
anoth
randomis
control
trial
use
cpap
vs
oxygen
alon
publish
studi
focus
evalu
efficaci
cpap
applic
term
oxygen
specif
popul
patient
pneumonia
moder
sever
nonhypercapn
hypoxemia
inclus
criteria
moder
acut
respiratori
failur
pao
fio
ratio
mmhg
respiratori
rate
breathsmin
patient
randomis
receiv
helmet
cpap
standard
oxygen
therapi
control
group
primari
endpoint
time
reach
pao
fio
ratio
mmhg
patient
reach
threshold
level
last
plan
arteri
blood
ga
measur
h
consid
failur
fortyseven
patient
recruit
randomis
cpap
control
patient
randomis
cpap
reach
endpoint
median
h
wherea
control
reach
endpoint
h
p
proport
patient
reach
primari
endpoint
cpap
group
among
control
p
one
hour
reach
primari
endpoint
patient
cpap
group
maintain
pao
fio
valu
author
conclud
cpap
applic
patient
moder
hypoxem
arf
due
cap
improv
oxygen
moreov
impress
find
rapid
effect
cpap
comparison
standard
oxygen
therapi
anoth
interest
find
vanish
oxygen
improv
cpap
discontinu
phenomenon
defin
author
onoff
effect
cpap
pneumonia
alreadi
seen
patient
pneumonia
treat
niv
therefor
order
obtain
physiolog
also
signific
clinic
effect
could
necessari
open
keep
open
lung
patient
pneumonia
applic
cpap
wait
antibiot
effect
conclus
studi
prove
effect
cpap
improv
ga
exchang
welldefin
model
hypoxem
arf
cap
author
conclud
studi
repres
proofofconcept
studi
could
sustain
develop
futur
trial
analys
clinic
outcom
possibl
advers
event
popul
patient
sever
cap
treat
cpap
trial
would
need
evalu
possibl
role
cpap
valid
safe
tool
manag
patient
cap
randomis
control
trial
defin
issu
recommend
use
techniqu
patient
cap
sever
respiratori
failur
reason
new
randomis
control
studi
compar
helmet
cpap
applic
oxygen
alon
patient
pneumonia
sever
acut
respiratori
failur
ongo
wwwclinicaltri
gov
inclus
criteria
arf
defin
dyspnoea
rest
respiratori
rate
breathmin
sign
respiratori
distress
pao
fio
ratio
evalu
oxygen
therapi
suppli
least
h
venturi
mask
fio
multicentr
intern
studi
still
enrol
patient
reach
sampl
size
patient
divid
two
balanc
group
treatment
primari
endpoint
develop
endotrach
intub
criteria
maintain
least
h
studi
first
randomis
control
trial
comparison
cpap
vs
oxygen
alon
cohort
patient
diagnosi
pneumonia
uniqu
caus
sever
acut
respiratori
failur
final
observ
retrospect
data
efficaci
cpap
niv
applic
pneumonia
publish
recent
patient
arf
pneumonia
author
describ
caseseri
patient
arf
due
pneumonia
treat
boussignac
cpap
helmet
system
bipap
vision
cpap
niv
effect
patient
term
clinic
arteri
blood
ga
improv
avoid
intub
patient
death
icu
hospit
median
durat
p
fig
initi
evolut
respiratori
rate
left
panel
arteri
hypoxemia
assess
arteri
oxygen
tension
inspir
oxygen
fraction
ratio
right
panel
patient
treat
cpap
plu
oxygen
compar
treat
oxygen
alon
baselin
min
initi
treatment
adapt
ventil
day
howev
favour
result
consid
view
studi
limit
sinc
small
retrospect
case
seri
patient
pneumonia
without
seriou
organ
involv
summari
evid
base
data
provid
literatur
cpap
applic
pneumonia
rel
robust
immunosuppress
popul
applic
niv
also
gener
strongli
recommend
howev
immunocompet
popul
prospect
randomis
control
trial
cpap
use
design
result
conclus
debat
data
trial
concord
regard
common
observ
cpap
applic
improv
ga
exchang
physiolog
variabl
howev
reliabl
welldesign
control
studi
avail
question
whether
cpap
use
patient
pneumonia
still
open
unlik
cpap
applic
acut
cpo
peep
pneumonia
may
improv
oxygen
may
impair
stroke
volum
may
counterbal
benefici
effect
moreov
oxygen
one
variabl
involv
convers
peep
applic
acut
cpo
part
treatment
sinc
benefici
effect
includ
respiratori
circulatori
perform
alveolar
recruit
lead
oxygen
improv
also
increas
frc
complianc
hand
heart
perform
favour
two
phenomena
decreas
transmur
lv
pressur
determin
respiratori
effort
decreas
induc
cpap
applic
decreas
venou
return
lack
improv
work
breath
applic
cpap
observ
lher
et
al
physiolog
studi
patient
acut
lung
injuri
mainli
caus
pneumonia
contrast
mark
improv
observ
applic
niv
may
also
explain
lack
clinic
benefit
cpap
immunocompet
patient
inde
randomis
control
trial
use
niv
patient
sever
ahrf
found
frequent
indic
intub
relev
featur
time
intub
presenc
sign
exhaust
summari
peculiar
relationship
cpap
applic
clinic
effect
acut
cpo
model
profoundli
differ
pneumonia
two
fundament
aspect
first
acut
cpo
peep
applic
induc
favour
physiolog
effect
cardiopulmonari
compart
side
respiratori
cardiocirculatori
wherea
pneumonia
effect
heart
may
detriment
mean
acut
cpo
tissu
perfus
favour
cpap
applic
second
pneumonia
benefici
respiratori
effect
oxygen
alveolar
recruit
repres
part
strategi
improv
tissu
perfus
oxygen
inde
tissu
perfus
depend
mean
arteri
pressur
latter
relat
part
arteri
blood
oxygen
also
haemoglobin
cardiac
output
henc
easi
understand
uniqu
improv
arteri
oxygen
suffici
assur
optim
tissu
perfus
therefor
pneumonia
crucial
alway
focus
triad
concur
ie
arteri
oxygen
cardiac
output
haemoglobin
recommend
approach
sever
sepsi
mainli
repres
pneumonia
clinic
exampl
know
normal
healthi
man
kg
mlmin
patient
pneumonia
pao
mmhg
room
air
hb
gdl
cardiac
output
l
min
around
mlmin
increas
pao
mmhg
increas
fio
andor
appli
peep
increas
around
mlmin
increas
still
less
half
normal
howev
patient
transfus
reach
haemoglobin
level
gdl
increas
almost
mlmin
final
cardiac
output
optimis
l
min
increas
exceed
mlmin
thu
approach
normal
valu
conclud
therefor
noninvas
ventil
cpap
particular
role
manag
arf
immunosuppress
popul
evidencebas
data
insuffici
recommend
use
immunocompet
popul
case
cpap
alon
consid
support
measur
increas
oxygen
part
approach
optimis
tissu
perfus
alway
aim
treatment
pneumonia
niv
may
also
use
true
support
fall
respiratori
pump
author
declar
conflict
interest
regard
subject
use
noninvas
ventil
patient
communityacquir
pneumonia
controversi
sinc
associ
high
rate
treatment
failur
compar
caus
sever
acut
respiratori
failur
popul
patient
communityacquir
pneumonia
demonstr
better
respons
noninvas
ventil
previou
cardiac
respiratori
diseas
particularli
chronic
obstruct
pulmonari
diseas
contrast
use
noninvas
ventil
patient
communityacquir
pneumonia
without
preexist
diseas
cautiou
strict
monitor
condit
sinc
increas
evid
unnecessari
delay
intub
patient
fail
treatment
noninvas
ventil
associ
lower
surviv
pulmonari
complic
immunosuppress
patient
associ
high
rate
intub
mortal
use
noninvas
ventil
patient
may
decreas
need
intub
improv
poor
outcom
associ
complic
continu
posit
airway
pressur
use
treat
acut
respiratori
failur
sever
condit
characteris
alveolar
collaps
extrem
use
patient
acut
cardiogen
pulmonari
oedema
efficaci
pneumonia
seem
limit
immunosuppress
patient
pulmonari
complic
convers
suffici
evid
efficaci
continu
posit
airway
pressur
immunocompet
patient
pneumonia
sever
acut
respiratori
failur
